Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 10Phase 3 7Phase 1/2 2Phase NA 1Phase 4 1Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Melanoma 2

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 37aldesleukin 26Interleukin-2 25Temozolomide 17fludarabine 16fludarabine phosphate 15trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Introns × Dermatologic × Clear all
NCT01743157 2013-08-29

BBI

California Pacific Medical Center Research Institute

Phase 1/2 Completed
24 enrolled
Dermatologic

Melanoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡